Related Experiment Video
Updated: May 28, 2026
10:02
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Ganoderma lucidum as a Functional Bioactive Candidate for Glycemic Regulation: Mechanisms, Preclinical Evidence, and
Bogdan Florea1,2, Doru Morar1, Corina Marina Kracunovic1
1Department of Internal Medicine, University of Life Sciences "King Mihai I" from Timisoara, 300645 Timisoara, Romania.
Metabolites
|May 26, 2026
Summary
Ganoderma lucidum shows potential for type 2 diabetes management, with preclinical studies suggesting hypoglycemic effects. However, clinical evidence remains insufficient, highlighting the need for further research and standardization.
Area of Science:
- Pharmacology and Nutraceutical Science
- Metabolic Disorders Research
- Traditional Medicine Efficacy Evaluation
Background:
- Type 2 diabetes mellitus (T2DM) is a global health concern driving interest in nutraceuticals.
- Ganoderma lucidum (Lingzhi/Reishi) is a medicinal mushroom with traditional use and emerging research in glycemic regulation.
- Existing reviews lack specific focus on the alignment of Ganoderma's taxonomic, chemical, preclinical, and clinical data for T2DM.
Purpose of the Study:
- To critically synthesize evidence on Ganoderma lucidum's hypoglycemic effects for T2DM.
- To evaluate bioactive compounds, molecular mechanisms, and translational limitations.
- To assess the consistency between preclinical findings and human clinical data.
Main Methods:
- Narrative review of literature from PubMed, Web of Science, Scopus, and Google Scholar up to October 2025.
- Inclusion of in vitro, in vivo animal, and human clinical trial studies.
- Focus on glycemic and metabolic outcomes of Ganoderma preparations.
Main Results:
- Preclinical studies suggest polysaccharides and triterpenoids in Ganoderma lucidum may improve insulin sensitivity, glucose uptake, and inhibit carbohydrate digestion.
- Mechanisms include AMPK/PI3K/Akt pathways, GLUT4 translocation, reduced gluconeogenesis, beta-cell protection, and gut microbiota modulation.
- Clinical trial results are heterogeneous, with one large trial showing no significant glycemic benefit.
Conclusions:
- Ganoderma lucidum exhibits strong mechanistic plausibility for antidiabetic effects.
- Current clinical evidence is insufficient to support its efficacy in managing type 2 diabetes.
- Future research requires species authentication, chemical standardization, and robust clinical trials.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...